14733-77-8

Basic information

• Product Name: 2(3H)-Benzoxazolone,5-amino-(9CI)
• Synonyms: 2(3H)-Benzoxazolone,5-amino-(9CI);5-Aminobenzoxazol-2(3H)-one;2(3H)-Benzoxazolone, 5-amino-;2-Benzoxazolinone, 5-amino-;5-Amino-2-benzoxazolinone;5-Amino-2-benzoxazolone;5-Aminobenzoxazolin-2-one;5-Aminobenzoxazolone
• CAS NO: 14733-77-8
• Molecular Formula: C₇H₆N₂O₂
• Molecular Weight: 150.14
• Product Categories: AMINEPRIMARY
• Mol File: 14733-77-8.mol

Chemical Properties

• Melting Point: 206-208 °C
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.438g/cm³
• Refractive Index: 1.659
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.07±0.70(Predicted)
• CAS DataBase Reference: 2(3H)-Benzoxazolone,5-amino-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2(3H)-Benzoxazolone,5-amino-(9CI)(14733-77-8)
• EPA Substance Registry System: 2(3H)-Benzoxazolone,5-amino-(9CI)(14733-77-8)

Safety Data

• Hazardous Substances Data: 14733-77-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2(3H)-Benzoxazolone,5-amino-(9CI) is used as a key intermediate in the synthesis of Nav1.1 activators, specifically for the preparation of Pyridazinone derivatives. These Nav1.1 activators play a crucial role in modulating the voltage-gated sodium channel 1.1, which is involved in the initiation and propagation of action potentials in neurons. The activation of this channel can be beneficial for treating certain neurological disorders and pain conditions.

InChI:InChI=1/C7H6N2O2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,8H2,(H,9,10)

Upstream product

• 99-57-0 2-hydroxy-5-nitroaniline 
• 64037-16-7 5-nitro-benzooxazol-2-ylamine 
• 64037-26-9 benzooxazole-2,5-diamine 
• 3889-13-2 5-nitro-3H-benzooxazol-2-one 

Downstream Products

• 1357101-83-7 N₂-(4-tert-butoxycarbonyl-3,5-dimethyl)phenyl-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine 
• 1357101-80-4 N₂-(3,4-dimethyl-5-hydroxymethyl)phenyl-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine 
• 1357101-78-0 N₂-(3-carboxy-4,5-dimethyl)phenyl-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine 
• 1357101-77-9 N₂-(3,4-dimethyl-5-methoxycarbonyl)phenyl-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine 
• 1357101-76-8 N₂-(3,5-dimethyl-4-methoxymethyl)phenyl-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine 
• 1357101-75-7 N₂-(3,5-dimethyl-4-hydroxymethyl)phenyl-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine 
• 1357101-73-5 N₂-(4-carboxy-3,5-dimethyl)phenyl-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine 
• 1357103-85-5 di-tert-butyl (5-(2-(4-fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)-2-oxobenzo[d]oxazol-3(2H)-yl)methyl phosphate 
• 1236666-76-4 N₂-(3,4,5-trimethyl)phenyl-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine 
• 1236667-40-5 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methylpyrimidin-4-yl)amino)benzo[d]oxazol-2(3H)-one 
• 1236670-87-3 2-chloro-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-4-pyrimidineamine 
• 1187889-72-0 3-oxo-N-(2-oxo-2,3-dihydro-benzooxazol-5-yl)-3-[4-(2-trifluoromethyl-benzoyl)-piperazin-1-yl]-propionamide 
• 14733-73-4 5-bromo-1,3-benzoxazol-2(3H)-one 

Relevant articles and documents

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of Formulas I-VI, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth. Formula I is exemplified below: Formula (i)

Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to novel pyrimide derivatives of formula (I): that are useful as kinase inhibitors. More particularly, the present invention relates to novel pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders.

NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE

The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

Benzimidazole derivatives, their preparation and use

A compound having the formula STR1 wherein R 1 is hydrogen, NH 2 or C 1-6 -alkyl which may be branched;X is O, S, NCN;Y is O, S;R 4, R 5, R 6 and R 7 independently of each other are hydrogen, halogen, CF 3, NO 2, NH 2, OH, C 1-6 -alkoxy, C( O)-phenyl or SO 2 NR I R II wherein R I and R II independently are hydrogen or C 1-6 -alkyl;R 11 is hydrogen, halogen, NO 2 or SO 2 NR''R"" wherein R'' and R"" independently are hydrogen or C 1-6 -alkyl;R 13 is hydrogen, halogen, phenyl, CF 3, NO 2 ;R 12 is hydrogen or together with R 13 forms a C 4-7 -carbocyclic ring which may be aromatic or partially saturated;R 14 is hydrogen or together with R 13 forms a C 4-7 -carbocyclic ring which may be aromatic or partially saturated;pharmaceutical compositions thereof,and a method of treating a disease in a mammal, including a human, responsive to opening of potassium channels, which comprises administering to a mammal in need thereof an effective amount of a compound as first above indicated, are disclosed.